首页> 外文期刊>Malaria Journal >Four years’ monitoring of in vitro sensitivity and candidate molecular markers of resistance of Plasmodium falciparum to artesunate-mefloquine combination in the Thai-Myanmar border
【24h】

Four years’ monitoring of in vitro sensitivity and candidate molecular markers of resistance of Plasmodium falciparum to artesunate-mefloquine combination in the Thai-Myanmar border

机译:四年监测泰缅边境对恶性疟原虫对青蒿琥酯-甲氟喹组合耐药的体外敏感性和候选分子标记

获取原文
           

摘要

Background The decline in efficacy of artesunate (AS) and mefloquine (MQ) is now the major concern in areas along the Thai-Cambodian and Thai-Myanmar borders. Methods The correlation between polymorphisms of pfatp6, pfcrt, pfmdr1 and pfmrp1 genes and in vitro sensitivity of Plasmodium falciparum isolates to the artemisinin-based combination therapy (ACT) components AS and MQ, including the previously used first-line anti-malarial drugs chloroquine (CQ) and quinine (QN) were investigated in a total of 119 P. falciparum isolates collected from patients with uncomplicated P. falciparum infection during 2006–2009. Results Reduced in vitro parasite sensitivity to AS [median (95% CI) IC50 3.4 (3.1-3.7) nM] was found in 42% of the isolates, whereas resistance to MQ [median (95% CI) IC50 54.1 (46.8-61.4) nM] accounted for 58% of the isolates. Amplification of pfmdr1 gene was strongly associated with a decline in susceptibility of P. falciparum isolates to AS, MQ and QN. Significant difference in IC50 values of AS, MQ and QN was observed among isolates carrying one, two, three, and ≥ four gene copies [median (95% CI) AS IC50: 1.6 (1.3-1.9), 1.8 (1.1-2.5), 2.9 (2.1-3.7) and 3.1 (2.5-3.7) nM, respectively; MQ IC50: 19.2 (15.8-22.6), 37.8 (10.7-64.8), 55.3 (47.7-62.9) and 63.6 (49.2-78.0) nM, respectively; and QN IC50: 183.0 (139.9-226.4), 256.4 (83.7-249.1), 329.5 (206.6-425.5) and 420.0 (475.2-475.6) nM, respectively]. The prevalence of isolates which were resistant to QN was reduced from 21.4% during the period 2006–2007 to 6.3% during the period 2008–2009. Pfmdr1 86Y was found to be associated with increased susceptibility of the parasite to MQ and QN. Pfmdr1 1034C was associated with decreased susceptibility to QN. Pfmrp1 191Y and 1390I were associated with increased susceptibility to CQ and QN, respectively. Conclusion High prevalence of CQ and MQ-resistant P. falciparum isolates was observed during the four-year observation period (2006–2009). AS sensitivity was declined, while QN sensitivity was improved. Pfmdr1 and pfmrp1 appear to be the key genes that modulate multidrug resistance in P. falciparum.
机译:背景技术青蒿琥酯(AS)和甲氟喹(MQ)的功效下降现在是泰国-柬埔寨和泰国-缅甸边界沿线地区的主要关注点。方法pfatp6,pfcrt,pfmdr1和pfmrp1基因的多态性与恶性疟原虫分离株对基于青蒿素的联合治疗(ACT)成分AS和MQ的体外敏感性之间的相关性,包括先前使用的一线抗疟疾药物氯喹(在2006–2009年期间,从无并发症恶性疟原虫感染患者中收集的119株恶性疟原虫分离株中共调查了CQ和奎宁(QN)。结果在42%的分离物中发现对AS的体外寄生虫敏感性降低[中位数(95%CI)IC50 3.4(3.1-3.7)nM],而对MQ [中位数(95%CI)IC50 54.1(46.8-61.4) )nM]占分离株的58%。 pfmdr1基因的扩增与恶性疟原虫对AS,MQ和QN的敏感性下降密切相关。在携带一,二,三和≥4个基因拷贝的分离株中,观察到AS,MQ和QN的IC50值存在显着差异[中位数(95%CI)AS IC50:1.6(1.3-1.9),1.8(1.1-2.5)分别为2.9(2.1-3.7)和3.1(2.5-3.7)nM; MQ IC50:分别为19.2(15.8-22.6),37.8(10.7-64.8),55.3(47.7-62.9)和63.6(49.2-78.0)nM;和QN IC50:分别为183.0(139.9-226.4),256.4(83.7-249.1),329.5(206.6-425.5)和420.0(475.2-475.6)nM。对QN耐药的分离株的患病率从2006-2007年的21.4%降低到2008-2009年的6.3%。发现Pfmdr1 86Y与该寄生虫对MQ和QN的敏感性增加有关。 Pfmdr1 1034C与对QN的敏感性降低有关。 Pfmrp1 191Y和1390I分别与CQ和QN敏感性增加有关。结论在四年的观察期(2006-2009年)中,发现了对CQ和MQ耐药的恶性疟原虫分离株的高流行。 AS敏感性下降,而QN敏感性提高。 Pfmdr1和pfmrp1似乎是调节恶性疟原虫多药耐药性的关键基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号